|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/22/20 Axogen, Inc. 8-K:8,9 7/22/20 11:193K Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 36K 2: EX-99.1 Miscellaneous Exhibit HTML 20K 7: R1 Document and Entity Information HTML 49K 9: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- axgn-20200722x8k_htm XML 16K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.LAB XBRL Labels -- axgn-20200722_lab XML 46K 5: EX-101.PRE XBRL Presentations -- axgn-20200722_pre XML 31K 3: EX-101.SCH XBRL Schema -- axgn-20200722 XSD 12K 10: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K 11: ZIP XBRL Zipped Folder -- 0001558370-20-008283-xbrl Zip 14K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form i 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i July 22, 2020
i AXOGEN, INC.
(Exact name of registrant as specified in its charter)
| | | | |
i Minnesota |
|
| i 41-1301878 | |
(State or other jurisdiction of | | (Commission File Number) | | (IRS Employer Identification No.) |
incorporation) | | | | |
| | |
i 13631 Progress Boulevard, i Suite 400, |
| |
i Alachua, i Florida | | i 32615 |
(Address of Principal Executive Offices) | | (Zip Code) |
| ||
| i ( i 386) 462-6800 / | |
Registrant’s telephone number, including area code | ||
| ||
| | |
(Former name or former address if changed since last report,) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | |
Title of each class | Trading Symbol(s) | Name of exchange on which registered |
i Common Stock, $0.01 par value | i AXGN | i The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On July 22, 2020, Axogen, Inc. (the “Company”) issued a press release announcing information regarding the Company’s RECON℠ study which supports its Biologic License Application Submission for Avance® Nerve Graft. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The information furnished pursuant to Item 8.01 of this Current Report, including Exhibit 99.1 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 | | |
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101) |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
Dated: July 22, 2020 | | |
| | |
| AXOGEN, INC. | |
| | |
| By: | |
| Name: | |
| Title: | General Counsel |
| | |
3
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 7/22/20 | None on these Dates | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/08/21 Axogen, Inc. 424B3 1:365K Toppan Merrill/FA |